| 1 |
Ion-Channel Antiepileptic Drugs: An Analytical Perspective on the Therapeutic Drug Monitoring (TDM) of Ezogabine, Lacosamide, and Zonisamide |
|
| | Roberto Mandrioli, Michele Protti, Lorenzo Marincich, Laura Mercolini | | | Analytica. 2021; 2(4): 171 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials |
|
| | Marie Selvy, Mélissa Cuménal, Nicolas Kerckhove, Christine Courteix, Jérôme Busserolles, David Balayssac | | | Expert Opinion on Drug Safety. 2020; 19(6): 707 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Zonisamide for the Treatment of Parkinson Disease: A Current Update |
|
| | Chengqian Li, Li Xue, Yumei Liu, Zhengjie Yang, Song Chi, Anmu Xie | | | Frontiers in Neuroscience. 2020; 14 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity |
|
| | Maiko T. Uemura, Takeshi Asano, Rie Hikawa, Hodaka Yamakado, Ryosuke Takahashi | | | Neuroscience Research. 2017; 124: 25 | | | [Pubmed] [Google Scholar] [DOI] | | | 5 |
The agony of the agonists: a review of impulsivity and withdrawal syndromes in Parkinson's disease treatment |
|
| | Andrea J Lindahl, Douglas G MacMahon | | | Future Neurology. 2015; 10(4): 357 | | | [Pubmed] [Google Scholar] [DOI] | |
|
